Study summary
FDA did not yet approve lutetium edotreotide
What was tested
The FDA decision on 177Lu-edotreotide (ITM-11), a radioligand tested against everolimus in the COMPETE trial.
What they found
- The FDA issued a complete response letter; the company said it raised no clinical issues.
What it means
A resubmission is likely; approval timing is uncertain.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.